RESEARCH ＆ DEVELOPMENT
Indications Under Development
Innovation With Speed
Reistone is focused on rapidly developing innovative medicines through global
collaborations within Research and Development
Patient Need Is Our Passion
Research & Development
At Reistone we devised our clinical development strategy around three key pillars: Science, People and Process. These key pillars serve as our guiding principles in clinical development.
2019/11/12 —— Irwin Wang – CEO, Reistone Biopharma, China
2019/06/28 —— Reistone Announces First Patient Dosed in Two Phase II Global Studies of SHR0302 JAK Inhibitor for Ulcerative Colitis and Crohn’s Disease
2018/10/22 —— Reistone Biopharma, a new Chinese biotech company ready to initiate its Ulcerative Colitis phase II clinical trial globally
Partnership is core to our business model. We are committed to partnering with R&D based global pharma and biotech companies to bring innovative medicines to patients.
People represent our key success pillar. We are keen to recruit new talent into Reistone where you can develop and achieve your career aspirations.
Shanghai (Headquarter), China
203,2F，Xiangke Road，Zhangjiang Hi-Tech Park，Pudong，
ZIP code: 201210
101,3F Air China Century Building，No.40 Xiangyun Rd，Chaoyang District Beijing 100027
ZIP code: 100027
1 Lincoln Street, 29
Boston, MA 02111, USA